Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05817045 · ClinicalTrials.gov registry record · NA
Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19
A NA study of COVID-19, sponsored by EmitBio.
- Completed
- Registry status
- NA
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT05817045: Completed NA study of COVID-19, sponsored by EmitBio.
NCT05817045 is a NA study of COVID-19 that has completed, run by EmitBio. The registered enrollment target is 330 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05817045, a NA study of COVID-19, has completed, sponsored by EmitBio.
- COMPLETED
- Registry status
- NA
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, sham controlled, stratified, pivotal efficacy and safety study of the EmitBio RD-X19 treatment device in Individuals 40 Years of age and older with Mild COVID-19 in the at-home setting.
Primary Outcome
Each of eight symptoms (cough, sore throat, nasal congestion, headache, chills and or sweats, myalgia, fatigue, and nausea (with or without vomiting)) will be rated on a 4-point scale from none (0) to severe (3). Time to sustained resolution of COVID-19 signs and symptoms as measured by the time (in hours) when all eight symptoms have been assessed by the subject as none (0) or mild (1) and all symptoms remain at or below 1 until study Day 14. Subjects that are hospitalized will be censored at 3
Conditions Studied
Interventions
- DEVICE Sham
- DEVICE RD-X19
Study Locations (20)
California
- 312 - Smart Cures Clinical Research - Anaheim
- 313 - Benchmark Southern California - Colton
- 307 - Ark Clinical Research - Long Beach
- 329 - Valley Clinical Trials - Northridge
- 348 - San Francisco Research Institute - San Francisco
- 328 - Mills Clinical Research - West Hollywood
Florida
- 305 - Indago Research and Health Center - Hialeah
- 321 - Helios Clinical Research - Kissimmee - Kissimmee
- 310 - Accel Research Sites - St. Petersburg - Largo
- 306 - Miami Clinical Research - Miami
Illinois
- 349 - Chicago Medical Research - Chicago
- 333 - Prime Global Research Inc. - Chicago
- 331 - Chicago Clinical Research Institute - Chicago
Arizona
- 322 - Desert Clinical Research/CCT Research - Mesa
- 347 - Velocity Clinical Research - Phoenix
Georgia
- 341 - Lifeline Primary Care / CCT Research - Lilburn
Iowa
- 345 - The Iowa Clinic/Avacare Legacy - West Des Moines
Kentucky
- 337 - Versailles Family Medicine/CCT Research - Versailles
Louisiana
- 346 - Benchmark Research - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2023-04-21 |
| Est. Completion | 2024-06-30 |
| Phase | NA |
What the finished NCT05817045 record still lists
NCT05817045 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Sham is the first listed.
NCT05817045 names 20 study sites across 9 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05817045 about?
NCT05817045 is a clinical study titled "Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19". This is a randomized, double-blind, sham controlled, stratified, pivotal efficacy and safety study of the EmitBio RD-X19 treatment device in Individuals 40 Years of age and older with Mild COVID-19 in the at-home setting.
What is the current status of trial NCT05817045?
This trial is currently completed. It is a NA study. The enrollment target is 330 participants. The study started on 2023-04-21. Estimated completion is 2024-06-30.
What conditions does trial NCT05817045 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05817045?
The interventions under investigation include: Sham (DEVICE), RD-X19 (DEVICE).
Who is sponsoring clinical trial NCT05817045?
This trial is sponsored by EmitBio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05817045 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05817045's enrollment target sits among peer trials
330 137th of 298 higher than 162 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Music Mindfulness Study 2a.
RECRUITING · NA
-
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
RECRUITING · NA
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Evaluating the Impact of Social Music
RECRUITING · NA
-
The SINCERE Intervention to Address COVID-19 Health Disparities
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI